Pre-clinical models of renal carcinoma and their utility in drug development

Brenda C. Salumbides, Kristin M. Lehet, Georges Ndikuyeze, Roberto Pili

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Significant progress has been made in the treatment of patients with advanced renal cancer. In addition to immunotherapy, there are several potentially distinct therapeutic approaches for targeting molecular pathways. The murine models detailed in this unit are useful for testing rational combination strategies. Moreover, animal models contribute immensely to the understanding of the genetic, epigenetic, and biological aspects of human disease. Compared to humans, rodent models are relatively short-lived and allow for the facile study of clinically relevant pathologies. Animal models for the study of renal cell carcinoma (RCC) are particularly useful for the development of new drugs for kidney cancer. Included in this unit are several in vivo models that are currently used to evaluate therapeutic approaches to renal cancer therapy and to investigate the pathophysiology of this condition. Included are both murine (RENCA) and renal cell carcinomas in subcutaneous and orthotopic models using tumor cell lines and human tumor tissue.

Original languageEnglish (US)
Pages (from-to)14.13.1-14.13.19
JournalCurrent Protocols in Pharmacology
Issue numberSUPPL.47
DOIs
StatePublished - Dec 1 2009
Externally publishedYes

Keywords

  • Angiogenesis
  • Bioluminescent imaging
  • Combination therapy
  • Immunotherapy
  • Metastastic tumor
  • Orthotopic implantation
  • Renal cell carcinoma
  • Retinoids
  • Subcutaneous implantation
  • Xenograft model

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Pre-clinical models of renal carcinoma and their utility in drug development'. Together they form a unique fingerprint.

  • Cite this